JP7469293B2 - Ａｇ１０の製剤 - Google Patents

Ａｇ１０の製剤 Download PDF

Info

Publication number
JP7469293B2
JP7469293B2 JP2021507989A JP2021507989A JP7469293B2 JP 7469293 B2 JP7469293 B2 JP 7469293B2 JP 2021507989 A JP2021507989 A JP 2021507989A JP 2021507989 A JP2021507989 A JP 2021507989A JP 7469293 B2 JP7469293 B2 JP 7469293B2
Authority
JP
Japan
Prior art keywords
tablet formulation
weight
fillers
tablet
pharma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021507989A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534189A (ja
Inventor
ジャーネリウス ジェスパー
マイケル メニング マーク
Original Assignee
エイドス セラピューティクス，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69524257&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7469293(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by エイドス セラピューティクス，インコーポレイティド filed Critical エイドス セラピューティクス，インコーポレイティド
Publication of JP2021534189A publication Critical patent/JP2021534189A/ja
Priority to JP2024060790A priority Critical patent/JP7860163B2/ja
Application granted granted Critical
Publication of JP7469293B2 publication Critical patent/JP7469293B2/ja
Priority to JP2026076282A priority patent/JP2026110857A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021507989A 2018-08-17 2019-08-16 Ａｇ１０の製剤 Active JP7469293B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024060790A JP7860163B2 (ja) 2018-08-17 2024-04-04 Ａｇ１０の製剤
JP2026076282A JP2026110857A (ja) 2018-08-17 2026-04-30 Ａｇ１０の製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862765154P 2018-08-17 2018-08-17
US62/765,154 2018-08-17
PCT/US2019/046789 WO2020037189A1 (en) 2018-08-17 2019-08-16 Formulations of ag10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024060790A Division JP7860163B2 (ja) 2018-08-17 2024-04-04 Ａｇ１０の製剤

Publications (2)

Publication Number Publication Date
JP2021534189A JP2021534189A (ja) 2021-12-09
JP7469293B2 true JP7469293B2 (ja) 2024-04-16

Family

ID=69524257

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021507989A Active JP7469293B2 (ja) 2018-08-17 2019-08-16 Ａｇ１０の製剤
JP2024060790A Active JP7860163B2 (ja) 2018-08-17 2024-04-04 Ａｇ１０の製剤
JP2026076282A Pending JP2026110857A (ja) 2018-08-17 2026-04-30 Ａｇ１０の製剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024060790A Active JP7860163B2 (ja) 2018-08-17 2024-04-04 Ａｇ１０の製剤
JP2026076282A Pending JP2026110857A (ja) 2018-08-17 2026-04-30 Ａｇ１０の製剤

Country Status (27)

Country Link
US (4) US11260047B2 (cg-RX-API-DMAC7.html)
EP (2) EP4647068A3 (cg-RX-API-DMAC7.html)
JP (3) JP7469293B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210046708A (cg-RX-API-DMAC7.html)
CN (2) CN112804998A (cg-RX-API-DMAC7.html)
AU (2) AU2019321583C1 (cg-RX-API-DMAC7.html)
BR (1) BR112020026493A2 (cg-RX-API-DMAC7.html)
CA (1) CA3104695A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021000289A1 (cg-RX-API-DMAC7.html)
DK (1) DK3836920T3 (cg-RX-API-DMAC7.html)
EA (1) EA202190561A1 (cg-RX-API-DMAC7.html)
ES (1) ES3055121T3 (cg-RX-API-DMAC7.html)
FI (1) FI3836920T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251603T1 (cg-RX-API-DMAC7.html)
IL (2) IL325404A (cg-RX-API-DMAC7.html)
LT (1) LT3836920T (cg-RX-API-DMAC7.html)
MA (1) MA53238A (cg-RX-API-DMAC7.html)
MX (1) MX2021001761A (cg-RX-API-DMAC7.html)
PL (1) PL3836920T3 (cg-RX-API-DMAC7.html)
PT (1) PT3836920T (cg-RX-API-DMAC7.html)
RS (1) RS67572B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202101393PA (cg-RX-API-DMAC7.html)
SI (1) SI3836920T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500463T1 (cg-RX-API-DMAC7.html)
TW (1) TWI834708B (cg-RX-API-DMAC7.html)
UA (1) UA128256C2 (cg-RX-API-DMAC7.html)
WO (1) WO2020037189A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3582773A4 (en) 2017-02-17 2021-03-10 Eidos Therapeutics, Inc. PROCESS FOR THE MANUFACTURING OF AG-10, ITS INTERMEDIATES AND SALTS THEREOF
WO2019183463A1 (en) 2018-03-23 2019-09-26 Eidos Therapeutics, Inc. Methods of treating ttr amyloidosis using ag10
LT3836920T (lt) 2018-08-17 2026-01-26 Eidos Therapeutics, Inc. Ag10 farmacinės formos
WO2023052652A1 (en) 2021-10-01 2023-04-06 Sandoz Ag Crystalline form of acoramidis hydrochloride
WO2025235883A1 (en) 2024-05-10 2025-11-13 Eidos Therapeutics, Inc. Acoramidis for use in the treatment of renal dysfunction

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008501680A (ja) 2004-06-04 2008-01-24 テバ ファーマシューティカル インダストリーズ リミティド イルベサルタンを含む医薬組成物
JP2009501801A (ja) 2005-07-18 2009-01-22 ホライゾン セラピューティクス， インコーポレイテッド イブプロフェンとファモチジンとを含有する医薬およびその投与
JP2013523833A (ja) 2010-04-07 2013-06-17 バーテックス ファーマシューティカルズ インコーポレイテッド ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の医薬組成物およびその投与
JP2016504338A (ja) 2012-12-21 2016-02-12 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ トランスサイレチン安定剤並びにトランスサイレチン・アミロイドーシス及びタンパク質−タンパク質相互作用を抑制するためのそれらの使用
US20180125789A1 (en) 2016-10-12 2018-05-10 Global Blood Therapeutics, Inc. Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
JP2018519297A (ja) 2015-06-30 2018-07-19 ギリアード サイエンシーズ， インコーポレイテッド テノホビルおよびエムトリシタビンを含む薬学的製剤

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
US4255329A (en) 1973-10-02 1981-03-10 Syva Company Double receptor fluorescent immunoassay
US4117149A (en) 1975-09-12 1978-09-26 Pfizer Inc. 4-oxo-4h-benzopyrans as animal growth promotants
US4261928A (en) 1977-08-05 1981-04-14 Sterling Drug Inc. 2-Benzoyl-8-(2-chloro-4-methoxyphenoxy)-1-phenyl-1-octanone
US4171365A (en) 1977-08-05 1979-10-16 Sterling Drug Inc. Antiviral aryloxyalkylpyrazoles
US4234725A (en) 1979-10-24 1980-11-18 Sterling Drug Inc. 4-[6-(2-Chloro-4-methoxyphenoxy)hexyl]-3,5-diethyl-1-[4-(4-morpholinyl)-1-oxobutyl]-1H-pyrazole
US4232161A (en) 1979-10-24 1980-11-04 Sterling Drug Inc. 4-[6-(2-Chloro-4-methoxyphenoxy)hexyl]-3,5-diethyl-1-(2-pyridinyl)-1H-pyrazole
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
US4668640A (en) 1981-12-11 1987-05-26 Abbott Laboratories Fluorescence polarization immunoassay utilizing substituted carboxyfluoresceins
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
GB2120242A (en) 1982-04-30 1983-11-30 Erba Farmitalia Ergoline derivatives
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4764521A (en) 1983-07-18 1988-08-16 Eli Lilly And Company Leukotriene antagonists and a method of use there as
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US6024975A (en) 1992-04-08 2000-02-15 Americare International Diagnostics, Inc. Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
US5315015A (en) 1992-11-10 1994-05-24 Hoffmann-La Roche Inc. Compounds having improved fluorescence in fluorescence polarization immunoassays and immunoassays utilizing same
TW260612B (cg-RX-API-DMAC7.html) 1993-01-05 1995-10-21 Asahi Chemical Ind
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
HU224548B1 (hu) 1993-04-07 2005-10-28 Taiho Pharmaceutical Co. Ltd. Tiazolidinszármazékok és ezeket tartalmazó gyógyszerkészítmények, valamint eljárás előállításukra
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
US5744368A (en) 1993-11-04 1998-04-28 Research Foundation Of State University Of New York Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR)
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US5983134A (en) 1995-04-23 1999-11-09 Electromagnetic Bracing Systems Inc. Electrophoretic cuff apparatus drug delivery system
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US6167301A (en) 1995-08-29 2000-12-26 Flower; Ronald J. Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US5985317A (en) 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
WO1998014179A1 (en) 1996-10-01 1998-04-09 Cima Labs Inc. Taste-masked microcapsule compositions and methods of manufacture
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
CA2275539A1 (en) 1997-10-28 1999-05-06 Bando Chemical Industries, Ltd. A transdermal patch and a method for manufacture of a substrate sheet therefor
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
US6256533B1 (en) 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
IL150524A0 (en) 2000-01-07 2003-02-12 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
JP2005513026A (ja) 2001-11-15 2005-05-12 インサイト サン ディエゴ インコーポレイテッド 高コレステロール血症、異脂肪血症および他の代謝障害；癌、および他の疾患を治療するｎ−置換複素環
PT1511710E (pt) 2002-05-31 2014-02-26 Proteotech Inc Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson
TW200403061A (en) 2002-06-04 2004-03-01 Glaxo Group Ltd Pharmaceutical compositions
WO2004096808A1 (en) 2003-04-28 2004-11-11 De Novo Pharmaceuticals Limited Triazine compounds and their use
US20050113394A1 (en) 2003-11-26 2005-05-26 Wood Allen W. Pharmaceutical compositions
US8026366B2 (en) 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
JP2007284350A (ja) 2004-07-27 2007-11-01 Takeda Chem Ind Ltd 糖尿病治療剤
WO2006088694A1 (en) 2005-02-14 2006-08-24 Wyeth SUBSTITUTED THIENYL AND FURYL ACYLGUANIDINES AS β-SECRETASE MODULATORS
US20070000505A1 (en) 2005-02-24 2007-01-04 Philip Morris Usa Inc. Smoking article with tobacco beads
ATE453384T1 (de) 2005-09-23 2010-01-15 Hoffmann La Roche Neue dosierformulierung
SG173409A1 (en) 2006-11-24 2011-08-29 Ac Immune Sa N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimers
EA200900821A1 (ru) 2006-12-22 2010-02-26 Новартис Аг Производные 1-аминометил-l-фенилциклогексана как ингибиторы дпп-iv (дипептидилпептидазы-iv)
AR065802A1 (es) 2007-03-22 2009-07-01 Schering Corp Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
BRPI0811446A2 (pt) 2007-05-11 2014-10-29 Lilly Co Eli " 2-[4-(pirazol-4-ilalquil)piperazin-1-il]-3-fenil pirazinas e piridinas e 3-[4-(pirazol-4-ilalquil)piperazin-1-il]-2-fenil piridinas como antagonistas de receptor 5-ht7"
KR20100017372A (ko) 2007-05-25 2010-02-16 애보트 게엠베하 운트 콤파니 카게 향대사성 글루타메이트 수용체 2（ｍｇｌｕ2 수용체）의 포지티브 조절자로서의 헤테로사이클릭 화합물
ES2351274T3 (es) 2007-06-06 2011-02-02 Torrent Pharmaceuticals Ltd Nuevos compuestos.
CN101790526A (zh) 2007-06-08 2010-07-28 雅培制药有限公司 用作激酶抑制剂的5-杂芳基取代的吲唑化合物
WO2009048557A1 (en) 2007-10-10 2009-04-16 Mallinckrodt Baker, Inc. Directly compressible high functionality granular microcrystalline cellulose based excipient, manufacturing process and use thereof
CN101868228B (zh) 2007-11-21 2016-12-07 大日本住友制药株式会社 口腔内崩解片
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
FR2926722B1 (fr) 2008-01-25 2010-09-03 Substipharm Dev Formulation pharmaceutique appropriee pour la preparation de comprimes orodispersibles de prednisolone
EA019033B1 (ru) 2008-03-26 2013-12-30 Новартис Аг Ингибиторы дезацетилазы в, основанные на гидроксамате
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
US8048887B2 (en) 2008-09-11 2011-11-01 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7994171B2 (en) 2008-09-11 2011-08-09 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
EP2937418B1 (en) 2008-10-20 2017-10-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of transthyretin
TR201805216T4 (en) 2008-10-28 2018-06-21 Arena Pharm Inc COMPOSITIONS OF A USEFUL 5-HT2A SEROTONINE RECEPTOR MODULATOR FOR THE TREATMENT OF RELATED DISORDERS
AR074199A1 (es) 2008-11-20 2010-12-29 Glaxosmithkline Llc Compuesto de 6-(4-pirimidinil)-1h-indazol, composiciones farmaceuticas que lo comprenden y su uso para preparar un medicamento util para el tratamiento o disminucion de la gravedad del cancer.
CA2777043C (en) 2009-10-14 2015-12-15 Schering Corporation Substituted piperidines that increase p53 activity and the uses thereof
AR079022A1 (es) 2009-11-02 2011-12-21 Sanofi Aventis Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
CA3002948C (en) 2009-11-13 2020-10-27 Astrazeneca Uk Limited Immediate release tablet formulations
US20110144211A1 (en) 2009-12-11 2011-06-16 Lars Hermann Use of microcrystalline cellulose for interfering with the extraction of ephedrine
EP2566333A4 (en) 2010-05-07 2014-04-02 Univ Leland Stanford Junior IDENTIFICATION OF STABILIZERS OF MULTIMEDER PROTEINS
JP5759457B2 (ja) 2010-06-29 2015-08-05 旭化成ケミカルズ株式会社 セルロースと無機化合物を含む複合粒子
CA2822039C (en) 2010-12-16 2019-05-28 Allergan, Inc. Sulfur derivatives as chemokine receptor modulators
CN103841962B (zh) 2011-07-07 2016-08-17 爱尔兰詹森科学公司 地瑞纳韦配制品
CA2848493A1 (en) 2011-09-14 2013-03-21 Celgene Corporation Formulations of cyclopropanecarboxylic acid {2-[(1s)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amide
WO2014118809A1 (en) 2013-01-29 2014-08-07 Actavis Group Ptc Ehf. Pharmaceutical composition with linezolid
EA032757B1 (ru) 2014-02-14 2019-07-31 Экселиксис, Инк. Кристаллические твердые формы n-{4-[(6,7-диметоксихинолин-4-ил)окси]фенил}-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, способы получения и способы применения
US20160045609A1 (en) 2014-08-14 2016-02-18 Mamoun M. Alhamadsheh Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
MX376083B (es) 2015-06-04 2025-03-07 Pfizer Formas de dosificacion solidas de palbociclib.
MX375424B (es) 2015-07-31 2025-03-06 Pfizer Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-il carbamato y derivados de 1,1,1-trifluoro-4- hidroxibutan-2-il carbamato como inhibidores de magl
EP3582773A4 (en) 2017-02-17 2021-03-10 Eidos Therapeutics, Inc. PROCESS FOR THE MANUFACTURING OF AG-10, ITS INTERMEDIATES AND SALTS THEREOF
WO2019046167A1 (en) 2017-08-30 2019-03-07 Acadia Pharmaceuticals Inc. PIMAVANSERIN FORMULATIONS
WO2019183463A1 (en) 2018-03-23 2019-09-26 Eidos Therapeutics, Inc. Methods of treating ttr amyloidosis using ag10
LT3836920T (lt) 2018-08-17 2026-01-26 Eidos Therapeutics, Inc. Ag10 farmacinės formos
AU2021266739B2 (en) 2020-05-06 2024-11-28 Corcept Therapeutics Incorporated Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators
AU2021378320A1 (en) 2020-11-11 2023-06-22 Spero Therapeutics, Inc. High dosage tebipenem pivoxil tablet formulation
US20230330006A1 (en) 2020-12-18 2023-10-19 Amneal Complex Products Rearch LLC Sustained Release Compositions Comprising Liothyronine
JP2026508526A (ja) 2023-03-01 2026-03-11 エイドス セラピューティクス，インコーポレイティド アコラミディスの投与を受けているｔｔｒアミロイドーシス患者における強力なトランスサイレチン（ｔｔｒ）安定化

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008501680A (ja) 2004-06-04 2008-01-24 テバ ファーマシューティカル インダストリーズ リミティド イルベサルタンを含む医薬組成物
JP2009501801A (ja) 2005-07-18 2009-01-22 ホライゾン セラピューティクス， インコーポレイテッド イブプロフェンとファモチジンとを含有する医薬およびその投与
JP2013523833A (ja) 2010-04-07 2013-06-17 バーテックス ファーマシューティカルズ インコーポレイテッド ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の医薬組成物およびその投与
JP2016504338A (ja) 2012-12-21 2016-02-12 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ トランスサイレチン安定剤並びにトランスサイレチン・アミロイドーシス及びタンパク質−タンパク質相互作用を抑制するためのそれらの使用
JP2018519297A (ja) 2015-06-30 2018-07-19 ギリアード サイエンシーズ， インコーポレイテッド テノホビルおよびエムトリシタビンを含む薬学的製剤
US20180125789A1 (en) 2016-10-12 2018-05-10 Global Blood Therapeutics, Inc. Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde

Also Published As

Publication number Publication date
US12539290B2 (en) 2026-02-03
JP2021534189A (ja) 2021-12-09
MX2021001761A (es) 2021-04-19
LT3836920T (lt) 2026-01-26
EP4647068A2 (en) 2025-11-12
US20200054607A1 (en) 2020-02-20
TWI834708B (zh) 2024-03-11
JP2026110857A (ja) 2026-07-02
US20220313661A1 (en) 2022-10-06
IL280906B2 (en) 2026-05-01
DK3836920T3 (da) 2025-12-22
RS67572B1 (sr) 2026-01-30
CL2021000289A1 (es) 2021-08-27
CA3104695A1 (en) 2020-02-20
HRP20251603T1 (hr) 2026-01-30
EP3836920A1 (en) 2021-06-23
US20260097014A1 (en) 2026-04-09
AU2019321583A1 (en) 2021-01-21
SI3836920T1 (sl) 2026-02-27
AU2019321583C1 (en) 2025-11-27
US12005043B2 (en) 2024-06-11
UA128256C2 (uk) 2024-05-22
EP3836920A4 (en) 2022-04-13
SG11202101393PA (en) 2021-03-30
KR20210046708A (ko) 2021-04-28
JP2024083460A (ja) 2024-06-21
AU2025226697A1 (en) 2025-09-25
PL3836920T3 (pl) 2026-02-23
IL280906B1 (en) 2026-01-01
US20250057811A1 (en) 2025-02-20
US11260047B2 (en) 2022-03-01
TW202021583A (zh) 2020-06-16
WO2020037189A1 (en) 2020-02-20
EP4647068A3 (en) 2026-02-25
PT3836920T (pt) 2025-12-02
ES3055121T3 (en) 2026-02-10
CN122056844A (zh) 2026-05-19
EP3836920B1 (en) 2025-10-01
SMT202500463T1 (it) 2026-01-12
NZ774039A (en) 2025-03-28
AU2019321583B2 (en) 2025-06-05
CN112804998A (zh) 2021-05-14
EA202190561A1 (ru) 2021-05-26
MA53238A (fr) 2022-04-13
BR112020026493A2 (pt) 2021-03-23
IL325404A (en) 2026-02-01
JP7860163B2 (ja) 2026-05-15
IL280906A (en) 2021-04-29
FI3836920T3 (fi) 2025-12-22

Similar Documents

Publication Publication Date Title
JP7860163B2 (ja) Ａｇ１０の製剤
WO2008064202A2 (en) Modified-release formulations of calcium receptor-active compounds
JP7581052B2 (ja) レナリドミドの経口用コーティング錠剤組成物
ES2533956T3 (es) Desfesoterodina en forma de una sal de ácido tartárico
US12290601B2 (en) Pharmaceutical composition comprising axitinib
US20090028935A1 (en) Carvedilol forms, compositions, and methods of preparation thereof
CN105492013A (zh) 用于管理恶心和呕吐的组合物
HK40056307B (en) Formulations of ag10
HK40056307A (en) Formulations of ag10
KR102330953B1 (ko) 소듐-1-[6-(모르폴린-4-일)피리미딘-4-일]-4-(1h-1,2,3-트리아졸-1-일)-1h-피라졸-5-올레이트를 함유하는 제약 투여 형태
NZ774039A9 (en) Formulations of ag10
EP3941443B1 (en) Sustained release composition comprising tapentadol oxalate and method of preparation thereof
WO2024100682A1 (en) Sustained release composition of hydroxyzine and it's process
EA046923B1 (ru) Препараты ag10
EP4456883A1 (en) Donepezil -memantine extended release capsule composition
HK1198466B (en) Prasugrel-containing immediate release stable oral pharmaceutical compositions
HK1198466A1 (en) Prasugrel-containing immediate release stable oral pharmaceutical compositions

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220812

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230627

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230630

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231227

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240305

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240404

R150 Certificate of patent or registration of utility model

Ref document number: 7469293

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150